Genextra “Innovative research in life science to develop novel therapies and tools”

Genextra is a holding that provides financial and managerial support to a group of four subsidiaries, focussed on science: Intercept (Nasdaq: ICPT), DAC, Congenia and Tethis.

Genextra guides their transition from a research driven entity to a self-standing biotech company. At Genextra they seek to identify innovative research in life science and create companies to foster the development of novel therapies and technologies.

They focus their efforts on addressing innovation in companies with strong science which are typically at a funding stage that ranges from seed capital to where Venture Capital normally invests.

Website: www.genextra.it